- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT06131801
Összetört és oldattá feloldott Venetoclax tabletták farmakokinetikai vizsgálata
Farmakokinetikai vizsgálat a Venetoclax tablettákkal összetört és oldattá oldott gyermekeknél és fiatal felnőtteknél rosszindulatú hematológiai daganatokban
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.
Primary Objectives
• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution
Secondary Objectives
- To evaluate the safety of crushed venetoclax tablets administered as an oral solution
- To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
- To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
- To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution
A tanulmány áttekintése
Állapot
Körülmények
- Limfóma
- Follikuláris limfóma
- Leukémia
- B-sejtes limfóma
- Hodgkin limfóma
- Burkitt limfóma
- AML
- Non Hodgkin limfóma
- Akut limfocitás leukémia
- Akut mielogén leukémia
- Diffúz nagy B-sejtes limfóma
- Hematológiai rosszindulatú daganat
- Krónikus mielogén leukémia
- Mieloproliferatív neoplazma
- T-sejtes limfóma
- Perifériás T-sejtes limfóma
- CML
- MINDEN
- Bőr B-sejtes limfóma
Részletes leírás
Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.
Tanulmány típusa
Beiratkozás (Becsült)
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Site Public Contact
- Telefonszám: (513) 636-2799
- E-mail: cancer@cchmc.org
Tanulmányi helyek
-
-
Colorado
-
Aurora, Colorado, Egyesült Államok, 80045
- Toborzás
- Children's Hospital Colorado
-
Kutatásvezető:
- Kelly Faulk, MD
-
Kapcsolatba lépni:
- Kelly Faulk, MD
- Telefonszám: 720-777-5771
- E-mail: Kelly.Faulk@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Egyesült Államok, 30329
- Még nincs toborzás
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital
-
Kapcsolatba lépni:
- Himalee Sabnis, MD, MS
- Telefonszám: 57922 404-785-3627
- E-mail: Himalee.sabnis@choa.org
-
Kutatásvezető:
- Himalee Sabnis, MD, MS
-
-
Ohio
-
Cincinnati, Ohio, Egyesült Államok, 45229
- Toborzás
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Egyesült Államok, 19104
- Toborzás
- Children's Hospital of Philadelphia
-
Kutatásvezető:
- Sarah Tasian, MD
-
Kapcsolatba lépni:
- Tasleema Patel
- Telefonszám: 917-818-6971
- E-mail: patelt6@chop.edu
-
-
Texas
-
Houston, Texas, Egyesült Államok, 77030
- Toborzás
- Texas Children's Hospital
-
Kapcsolatba lépni:
- Michelle Redell, MD
- Telefonszám: 832-822-4242
- E-mail: mlredell@texaschildrens.org
-
Kapcsolatba lépni:
- Grace Anand
- Telefonszám: 832-824-7705
- E-mail: gxanand@texaschildrens.org
-
Kutatásvezető:
- Michelle Redell, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Egyesült Államok, 53226
- Toborzás
- Children's Hospital of Wisconsin
-
Kutatásvezető:
- Zachary Graff, MD
-
Kapcsolatba lépni:
- Kira Mielke
- E-mail: kmielke@mcw.edu
-
Kapcsolatba lépni:
- Kara Nelson
- E-mail: knelson@mcw.edu
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Mintavételi módszer
Tanulmányi populáció
Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
Patients must be <39 years of age at time of study enrollment.
Leírás
Inclusion Criteria:
- Age: Patients must be <39 years of age at time of study enrollment
- Diagnosis: Patients may have a diagnosis of any hematologic malignancy
- Central access: Patients must have an existing venous or arterial access line for PK blood draws
- Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
- Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
- Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.
Exclusion Criteria:
- Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
- Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Megfigyelési modellek: OTHER
- Időperspektívák: PROSPECTIVE
Kohorszok és beavatkozások
Csoport / Kohorsz |
Beavatkozás / kezelés |
|---|---|
|
Children and Young Adults
Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care. |
Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care. |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Időkeret: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Időkeret: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Időkeret: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Időkeret: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Időkeret: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Időkeret: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Időkeret: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Időkeret: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Időkeret: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Időkeret: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Időkeret: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Időkeret: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
Együttműködők és nyomozók
Nyomozók
- Kutatásvezető: Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Patológiás folyamatok
- Neoplazmák webhelyenként
- Neoplazmák
- Krónikus betegség
- Betegség tulajdonságai
- Immunrendszeri betegségek
- Fertőzések
- Vírusos betegségek
- Neoplazmák szövettani típus szerint
- Hematológiai betegségek
- DNS vírusfertőzések
- Nyirokrendszeri betegségek
- Limfoproliferatív rendellenességek
- Immunproliferatív rendellenességek
- Leukémia, mieloid
- Csontvelő-betegségek
- Leukémia, limfoid
- Epstein-Barr vírusfertőzések
- Herpesviridae fertőzések
- Tumor vírusfertőzések
- Kóros állapotok, jelek és tünetek
- Hemikus és nyirokbetegségek
- Leukémia
- Leukémia, mieloid, akut
- Hematológiai neoplazmák
- Limfóma
- Limfóma, B-sejt
- Limfóma, nagy B-sejtes, diffúz
- Prekurzor sejt limfoblaszt leukémia-limfóma
- Burkitt limfóma
- Limfóma, non-Hodgkin
- Limfóma, follikuláris
- Mieloproliferatív rendellenességek
- Hodgkin-kór
- Limfóma, T-sejt
- Limfóma, T-sejt, Perifériás
- Leukémia, mielogén, krónikus, BCR-ABL pozitív
Egyéb vizsgálati azonosító számok
- Venetoclax PK
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .